H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Yahoo! Finance
Wainwright raised the firm's price target on BioMarin to $60 from $55 with a Neutral rating on the shares. This sentiment was announced amid the acquisition of Amicus Therapeutics Inc. (NASDAQ: FOLD ), which the firm described as a move that stabilizes long-term cash flows, though H.C. Wainwright also noted that peak sales won't materialize until the 2030s. Therefore, Voxzogo will remain the primary driver of BioMarin's stock value in the interim. On December 19, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Amicus Therapeutics announced a definitive agreement for BioMarin to acquire Amicus in an all-cash transaction valued at ~$4.8 billion. Under the terms of the deal, BioMarin will pay $14.50 per share. The Boards of Directors of both companies have unanimously approved the merger, which is expected to close in Q2 2026, pending regulatory clearances and Amicus stockholder approval. The acquisition strategically expands BioMarin's leadership in rare diseases by adding two high-g
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- Making U.S. biotech more competitive with China's could help rare disease patients, experts say [CNBC]CNBC
- Does BioMarin Pharmaceutical (BMRN) Price Weakness Contrast With Its Cash Flow Valuation? [Yahoo! Finance]Yahoo! Finance
- BMRN or TARS: Which Is the Better Value Stock Right Now? [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference [Yahoo! Finance]Yahoo! Finance
- BioMarin Appoints Arpit Davé Chief Digital and Information Officer [Yahoo! Finance]Yahoo! Finance
BMRN
Earnings
- 10/27/25 - Miss
BMRN
Sec Filings
- 1/12/26 - Form 8-K
- 12/22/25 - Form 8-K
- 12/19/25 - Form 8-K
- BMRN's page on the SEC website